Oncoinvent ASA (ONCIN) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Oncoinvent ASA (ONCIN) has a cash flow conversion efficiency ratio of -1.103x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Nkr-73.90 Million ≈ $-7.78 Million USD) by net assets (Nkr67.00 Million ≈ $7.05 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See ONCIN equity financing ratio to measure how much of total assets are equity-financed.
Oncoinvent ASA - Cash Flow Conversion Efficiency Trend (2021–2025)
This chart illustrates how Oncoinvent ASA's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore cash flow to debt ratio of Oncoinvent ASA to assess how comfortably operating cash covers total debt obligations.
Oncoinvent ASA Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Oncoinvent ASA ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Incross Co. Ltd
KQ:216050
|
-0.036x |
|
RAIZ Invest Ltd
AU:RZI
|
0.054x |
|
APS Energia S.A.
WAR:APE
|
-0.353x |
|
LPS Brasil - Consultoria de Imóveis S.A
SA:LPSB3
|
0.085x |
|
Salter Brothers Emerging Companies Ltd
AU:SB2
|
0.018x |
|
LOOP INDUSTRIES DL-001
F:3L9
|
0.241x |
|
Mudajaya Group Bhd
KLSE:5085
|
-0.012x |
|
Green Cross Medical Science Corporation
KQ:142280
|
-0.003x |
Annual Cash Flow Conversion Efficiency for Oncoinvent ASA (2021–2025)
The table below shows the annual cash flow conversion efficiency of Oncoinvent ASA from 2021 to 2025. For the full company profile with market capitalisation and key ratios, see Oncoinvent ASA (ONCIN) market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | Nkr146.32 Million ≈ $15.40 Million |
Nkr-131.19 Million ≈ $-13.80 Million |
-0.897x | +36.62% |
| 2024-12-31 | Nkr108.33 Million ≈ $11.40 Million |
Nkr-153.24 Million ≈ $-16.13 Million |
-1.415x | -30.56% |
| 2023-12-31 | Nkr127.48 Million ≈ $13.41 Million |
Nkr-138.11 Million ≈ $-14.53 Million |
-1.083x | +66.73% |
| 2022-12-31 | Nkr88.50 Million ≈ $9.31 Million |
Nkr-288.23 Million ≈ $-30.33 Million |
-3.257x | -312.75% |
| 2021-12-31 | Nkr384.43 Million ≈ $40.45 Million |
Nkr-303.34 Million ≈ $-31.92 Million |
-0.789x | -- |
About Oncoinvent ASA
Oncoinvent ASA, a clinical stage company, develops radiopharmaceutical therapies against cancer. Its lead product candidate is Radspherin, an alpha-radiation therapy candidate for treating cancer that have spread to body cavities, including peritoneum in two phase 1/2a trials and one randomized phase 2 trial. The company is based in Oslo, Norway.